SRRK Stock Forecast & Price Target

Scholar Rock Holding is a strong buy based on their promising pipeline of potential treatments for rare neuromuscular diseases, including apitegromab and SRK-439. The recent FDA acceptance of the apitegromab BLA and completed Catalent Indiana reinspection provide significant regulatory de-risking and a clear path to commercial supply in early 3Q26. With a strong risk/reward profile and potential for multi-blockbuster success, SRRK's stock has a 12-month price target of $65, which is based on an equally weighted composite of a 25x multiple of taxed FY34 GAAP EPS and an NPV of the company's key programs. However, it is important to note that there are risks to this outlook, including potential competition and limitations in addressable market. Overall, SRRK's stock has a positive outlook and is expected to see continued growth with the potential for near-term product launches and ongoing clinical trials.

Scholar Rock Holding is facing risks with their regulatory pathways and timelines due to uncertainty with classification and facility prioritization, as well as potential delays in payer dynamics and priority review voucher monetization. Additionally, while their resubmission of the BLA for apitegromab in SMA is a key de-risking event, it may face competition from other muscle-directed therapies. The company's pipeline is on track, but there is still uncertainty with their next-generation highly selective subQ myostatin inhibitor and the strategic positioning of this therapy. Overall, there are several uncertainties and risks in the company's future, making me hold a negative outlook on this stock.